A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : LC / lanthanum carbonate

[Related PubMed/MEDLINE]
Total Number of Papers: 66
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   LC  (>> Co-occurring Abbreviation)
Long Form:   lanthanum carbonate
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Comparison of the effects of lanthanum carbonate and calcium carbonate on the progression of cardiac valvular calcification after initiation of hemodialysis. CC, CVC, CVCS, PS
2019 Effects of lanthanum carbonate on bone markers and bone mineral density in incident hemodialysis patients. BAP, BMD, CC, HD, iPTH, OC, TRACP-5b
2019 Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial. FGF23, NAM
2019 Effects of oral activated charcoal on hyperphosphatemia and vascular calcification in Chinese patients with stage 3-4 chronic kidney disease. CACS, CC, CKD, MDCT, OAC
2019 The effect of lanthanum carbonate on calciprotein particles in hemodialysis patients. ACI, Ca, CC, CPP, HCPP, HD, LCPP
2018 A meta-analysis of phosphate binders lanthanum carbonate versus sevelamer hydrochloride in patients with end-stage renal disease undergoing hemodialysis. ALP, ESRD, RCTs, SH
2018 Effect of combined vitamin D receptor activator and lanthanum carbonate on serum fibroblast growth factor 23 level in predialysis patients (CVD-LAF study): design and method. CKD, FGF23, PTH, VDRA
2018 Effect of Lanthanum Carbonate on All-Cause Mortality in Patients Receiving Maintenance Hemodialysis: a Meta-Analysis of Randomized Controlled Trials. CI, OR, RCTs
2017 A Combined Deposition of Lanthanum and beta2-Microglobulin-Related Amyloid in the Gastroduodenal Mucosa of Hemodialysis-Dependent Patients: An Immunohistochemical, Electron Microscopic, and Energy Dispersive X-Ray Spectrometric Analysis. Abeta2M
10  2017 Design and baseline characteristics of the LANDMARK study. Ca, CC
11  2017 Effect of lanthanum carbonate on coronary artery calcification and bone mineral density in maintenance hemodialysis patients with diabetes complicated with adynamic bone disease: A prospective pilot study. ABD, BMD, CAC, CACS, CC, MHD
12  2016 Impact of Lanthanum Carbonate on Prognosis of Chronic Hemodialysis Patients: A Retrospective Cohort Study (Kawashima Study). ---
13  2016 Lanthanum deposition in the gastrointestinal mucosa and regional lymph nodes in dialysis patients: Analysis of surgically excised specimens and review of the literature. ESD, ESRD, GI
14  2015 Cost effectiveness of lanthanum carbonate in chronic kidney disease patients in Spain before and during dialysis. CB, CKD, PSA, QALYs
15  2015 Cost-Minimization Analysis of Direct Cost of Sevelamer Carbonate and Lanthanum Carbonate in the Treatment of Patients with Chronic Kidney Disease Not on Dialysis in Bulgaria. CKD, SC
16  2015 Effects of lanthanum carbonate versus calcium carbonate on vascular stiffness and bone mineral metabolism in hemodialysis patients with type 2 diabetes mellitus: a randomized controlled trial. BAP, baPWV, BMD, CC, HD, IMT, OC
17  2015 Peculiar histiocytic lesions with massive lanthanum deposition in dialysis patients treated with lanthanum carbonate. ---
18  2015 Possibility of lanthanum absorption in the stomach. ---
19  2015 Sevalamer Hydrochloride, Sevelamer Carbonate and Lanthanum Carbonate: In Vitro and In Vivo Effects on Gastric Environment. HD, PPI, SC, SH
20  2014 Clinical effects of long-term (36-month) lanthanum carbonate administration in hemodialysis patients in Japan. ---
21  2014 Cost-minimization analysis of lanthanum carbonate versus sevelamer hydrochloride in US patients with end-stage renal disease. AWP, ESRD, SH, WAC
22  2014 Effect of lanthanum carbonate versus calcium-based phosphate binders in dialysis patients: a meta-analysis. ---
23  2014 Effects of change in the formulation of lanthanum carbonate on laboratory parameters. HD
24  2014 Efficacy and safety of lanthanum carbonate in pre-dialysis CKD patients with hyperphosphatemia: a randomized trial. CKD, ITT
25  2014 Efficacy and tolerability of lanthanum carbonate in treatment of hyperphosphatemia patients receiving dialysis--a systematic review and meta-analysis of randomized controlled trials. OR, RCTs, SMD
26  2014 Evaluation of aortic calcification with lanthanum carbonate vs. calcium-based phosphate binders in maintenance hemodialysis patients with type 2 diabetes mellitus: an open-label randomized controlled trial. ACI, CC, CKD-MBD, DM, HD, VC
27  2014 Increase in the dosage amount of vitamin D3 preparations by switching from calcium carbonate to lanthanum carbonate. Ca
28  2014 Is granular formulation of lanthanum carbonate more effective than chewable tablets? ---
29  2014 Multicenter study on the long-term (3-year) efficacy of lanthanum carbonate in dialysis patients. Ca, PTH
30  2014 Questionnaire survey and serum phosphorus levels in maintenance hemodialysis patients switching lanthanum carbonate formulation from chewable tablets to granules. ---
31  2014 Real-world dose-relativity, tablet burden, and cost comparison of conversion between sevelamer hydrochloride/carbonate and lanthanum carbonate monotherapies. ESRD, FAP, L-S, S-L, SH/C
32  2013 Additional reduction in serum phosphorus levels by pulverized lanthanum carbonate chewable in hemodialysis patients. P levels
33  2013 Differential effects of phosphate binders on pre-dialysis serum bicarbonate in end-stage kidney disease patients on maintenance haemodialysis. Al, Ca, SD 2.56, SD 2.62, SH
34  2013 Effects and safety of lanthanum carbonate in end stage renal disease patients with hyperphosphatemia: a meta-analysis--system review of lanthanum carbonate. ESRD
35  2013 Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD. FGF23
36  2013 Effects of switching from calcium carbonate to lanthanum carbonate on bone mineral metabolism in hemodialysis patients. Ca, CC, HD, IL-6, P levels, PTH
37  2013 Efficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: a systematic review. Ca P, CC, CKD-MBD, iPTH, LDL, RCTs, SH
38  2013 Efficacy of oral powder compared with chewable tablets for lanthanum carbonate administration in hemodialysis patients. ---
39  2013 Lanthanum carbonate delays progression of coronary artery calcification compared with calcium-based phosphate binders in patients on hemodialysis: a pilot study. Ca, CAC, CC, HD, iPTH
40  2013 The real-world dose-relativity of sevelamer hydrochloride and lanthanum carbonate monotherapy in patients with end-stage renal disease. ESRD, SH
41  2013 Three-year follow-up of lanthanum carbonate therapy in hemodialysis patients. CC, P levels, SH
42  2012 Assessment of pharmacodynamic equivalence and tolerability of lanthanum carbonate oral powder and tablet formulations: a single-center, randomized, open-label, 2-period crossover study in healthy subjects. LS
43  2012 Clinical usefulness of lanthanum carbonate for serum phosphate control in difficult patients. ---
44  2012 Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective. CC, CI, QALYs, SH
45  2012 Dissociation between progression of coronary artery calcification and endothelial function in hemodialysis patients: a prospective pilot study. CAC, HD
46  2012 Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: a crossover study. CaC, HD
47  2012 Efficacy and safety of lanthanum carbonate in German patients on dialysis. ESRD, SP
48  2012 Encephalopathy in a dialysis patient treated with lanthanum carbonate (LC). ---
49  2012 Lanthanum, constipation, bafflying X-rays and a perforated colonic diverticulum. ---
50  2012 Randomized crossover study of the efficacy and safety of sevelamer hydrochloride and lanthanum carbonate in Japanese patients undergoing hemodialysis. AEs, PROBE, SH
51  2011 Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial. BMD, CC, HD, HU, SFA, VC
52  2011 Clinical efficacy and cost-effectiveness of lanthanum carbonate as second-line therapy in hemodialysis patients in Japan. QALYs
53  2011 Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis. CB, CKD, QALYs, SP
54  2011 Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a US payer perspective. CVD, ESRD, ICERs, ITT, LYS, PSA, QALYs, SH
55  2011 Effect of lanthanum carbonate treatment on bone in Japanese dialysis patients with hyperphosphatemia. ---
56  2011 Lanthanum carbonate provides control of phosphorus levels in patients new to phosphate binder therapy and patients changed from other phosphate binders. CKD
57  2011 Lanthanum carbonate versus sevelamer hydrochloride: improvement of metabolic acidosis and hyperkalemia in hemodialysis patients. SH
58  2011 Signal intensity of lanthanum carbonate on magnetic resonance images: phantom study. MRI, SI, WIs
59  2010 A comparative study of 2 new phosphate binders (sevelamer and lanthanum carbonate) in routine clinical practice. ---
60  2010 Lanthanum carbonate is an effective hypophosphatemic agent for hemodialysis patients intolerant of other phosphate binders. ---
61  2009 Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study. SH, SP
62  2008 Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years. ---
63  2007 Relative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochloride. SH
64  2007 The cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in patients with end-stage renal disease. CC, ESRD, QALYs
65  2006 Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. CC
66  2003 A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. CC, ROD